Fabrice Lucien, PhD
@flscientist
Followers
565
Following
2K
Media
97
Statuses
945
🇫🇷🇨🇦🇺🇸 Assistant Professor of Urology & Immunology - Mayo Clinic - Basic and Translational Research - Liquid biopsies and next-gen cancer immunotherapies
Minnesota, USA
Joined December 2016
A novel PD-L1 inhibitor to reprogram myeloid cells and boost antitumor immunity. Beautiful preclinical work led by @michellehsuu under the mentorship of @hd_DongMDPhD . One step closer to clinical trials. @MayoUrology @MayoCancerCare
New #JITC article: Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansion https://t.co/OdQDEb1uND
@flscientist @hd_DongMDPhD
1
1
6
When the organizers ask you to send the slides in advance
21
53
974
Such an honor to receive the @PCFnews Challenge Award with the Dream Team: @aadel_chaudhuri @AOSartor @JakeOrmeMDPhD @RPachynski @ChrisMaher_Lab @pradeep198212! Elisa Ledet. Pushing boundaries of liquid biopsy with EVs and cfRNA in CRPC @MayoUrology @MayoRadOnc @MayoCancerCare
Truly honored and grateful to be awarded the PCF Challenge Award with this incredible group of friends and collaborators + my super-⭐️ mentee @pradeep198212! Quite the team! @AOSartor @ChrisMaher_Lab @RPachynski @JakeOrmeMDPhD @flscientist Elisa Ledet
2
6
31
Truly honored and grateful to be awarded the PCF Challenge Award with this incredible group of friends and collaborators + my super-⭐️ mentee @pradeep198212! Quite the team! @AOSartor @ChrisMaher_Lab @RPachynski @JakeOrmeMDPhD @flscientist Elisa Ledet
2
8
37
⭐️ Excellent poster presentation by @AJangMD on extracellular vesicles (EVs) as emerging biomarkers in bladder cancer👉Excited to see more work coming from this group! #BinaytaraPO25 @urotoday
0
3
5
My good friend Oliver Sartor (@AOSartor) on the big screen at #PCF @PCFnews!! Grateful for all of Oliver’s support of our collaborative #teamscience research ☺️
0
1
16
⚡️LBA Pres Sym #3⚡️ IMvigor011: Ph 3 RCT of ctDNA-guide adjv Atezo vs PBO in MIBC @urotoday #ESMO25 @tompowles1 @NEJM 🌐n=250 ctDNA+, 2:1 Atezo (167) vs PBO (83) 🌐🔼DFS: HR 0.64, 95%CI 0.47, 0.87; p=0.0047 🌐🔼OS: HR 0.59, 95%CI 0.39, 0.90; p=0.0131 🌐Gr 3/4 AE: 28.5% vs 21.7%
0
8
14
I'll have my take on the most important trials from #ESMO25 soon on my regular ESMO roundup video, so stay tuned. In the meantime, please consider these general points before you start claiming every trial with a P < 0.05 is the new standard of care. You don't need to think
8
18
60
A fascinating study shows that the longest lived-rodent evolved a cGAS variant to boosts DNA repair while dampening inflammation. Uncoupling genome surveillance from inflammation may be the secret to longevity #aging #inflammation
science.org
Efficient DNA repair might make possible the longevity of naked mole-rats. However, whether they have distinctive mechanisms to optimize functions of DNA repair suppressors is unclear. We find that...
0
71
301
Nobel Prize of Phys and Med 2025 recognizing breakthroughs in discovering regulatory T cells and their role in human immune control. #immunology #NobelPrize
BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”
0
3
10
Kidney injury molecule (KIM-1) is a strongly prognostic circulating biomarker & represents molecular residual disease in renal cancer. It potentially identifies responders to immunotherapy like ctDNA in bladder cancer. It is described for the 1st time in RCC in @Annals_Oncology
1
64
207
😎 You can already submit your abstracts for #ISEV2026, in Puerto Rico! 🌴 Submit before 13th January 2026, there will be NO late breaking submission https://t.co/eGnftjHZBM
@flscientist @jvburnier @TsuneyaIkezu @dsouzalab
0
3
6
In analysis of over 2,000 open RC patients, Mayo Clinic researchers found that prophylactic iNPWT was associated with lower odds of SSI. Further investigation is warranted though this low cost/risk intervention may reduce morbidity for select patients https://t.co/IIsWJzfsZC
1
10
40
IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last https://t.co/dPqlvr2rnV
9
113
288
@DrAndrewLoblaw We've got just that! https://t.co/EE69tST3ma Stay tuned for more.
ascopubs.org
424Background: Advances in prostate cancer (PC) care have led to a 98% 10-year survival rate. Prostate Specific Antigen (PSA) is the primary method of follow-up after definitive radiotherapy (RT),...
0
4
13
Delaying the use of ADT in oligorecurrent prostate cancer treated with SBRT but for who? Integration of imaging- and blood-based tumor burden estimation to select the right patients. @MayoUrology @MayoRadOnc @MayoCancerCare
https://t.co/phstygBnbv
pubmed.ncbi.nlm.nih.gov
Distant metastasis marks a critical transition in prostate cancer, separating potentially curable from canonically incurable disease. Oligometastatic disease, defined as limited metastases (e.g.,...
1
2
11
Congrats on @MayoUrology published study led by Drs @VRodriguezBravo and @DomingoDomenech discover that nucleoplasm-residing nucleoporins drive #ProstateCancer progression & immune evasion by switching on oncogenic signaling from deep within the nucleus! https://t.co/99Kmakz161
2
12
40
Our new humanized both PD-1 and PD-L1 mice are now available at the Jax lab with an RRID. Thank you all for your interest in use of this mouse model to shorten preclinical and clinical space for targeting this pathway. The link for strain details:
0
4
26
😱 Updates on #NCI R01 payline: 4th percentile for EI/NI, 10th %ile for ESI. Awarded R01: 17% budget cuts R21 payline: 7%ile https://t.co/eYNmw2WMxC
cancer.gov
NCI funding policy for research project grant (RPG) awards reflects the funding goals of the institute, NIH, and HHS.
1
0
0
What does it take to translate urinary EV biomarkers to the clinic? Glad to have contributed to this excellent review led by Marvin Droste and Uta Erdbrügger in @ISEV_Journals @IsevOrg
https://t.co/48KGpD40Gu
isevjournals.onlinelibrary.wiley.com
Despite remarkable interest in the biomarker potential of urinary extracellular vesicles (uEVs) and the identification of numerous promising candidates, their clinical translation still presents...
0
3
10